Will WVE-007 Phase IIa 6-month data show total body weight loss of 5% or greater in the 240mg cohort?
Current Prediction
Why This Question Matters
WVE-007 6-month weight loss data is the single most important near-term catalyst. The Myth Meter flagged elevated expectations, while the Moat Mapper identified the obesity program as a genuine differentiator. Above 5% total body weight loss at 6 months would validate the mechanism; below would deflate the obesity narrative and potentially reprice the stock materially lower.
Prediction Distribution
Individual Predictions(9 runs)
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Multi-dose should amplify Phase I effect provides partial support, but phase i 3-month only showed ~2-3% weight loss creates counterweight. Probability: 0.33.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Multi-dose should amplify Phase I effect provides partial support, but phase i 3-month only showed ~2-3% weight loss creates counterweight. Probability: 0.45.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Multi-dose should amplify Phase I effect provides partial support, but phase i 3-month only showed ~2-3% weight loss creates counterweight. Probability: 0.25.
Base rate evidence: phase i 3-month only showed ~2-3% weight loss. Partial offset from multi-dose should amplify phase i effect. Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Probability: 0.34.
Base rate evidence: phase i 3-month only showed ~2-3% weight loss. Partial offset from multi-dose should amplify phase i effect. Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Probability: 0.36.
Base rate evidence: phase i 3-month only showed ~2-3% weight loss. Partial offset from multi-dose should amplify phase i effect. Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Probability: 0.31.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Balance of evidence suggests 0.39 probability. Primary support: multi-dose should amplify phase i effect. Main counterargument: phase i 3-month only showed ~2-3% weight loss.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Balance of evidence suggests 0.38 probability. Primary support: multi-dose should amplify phase i effect. Main counterargument: phase i 3-month only showed ~2-3% weight loss.
Phase I data suggests 5% is borderline - requires meaningful amplification from single to multi-dose. Balance of evidence suggests 0.52 probability. Primary support: multi-dose should amplify phase i effect. Main counterargument: phase i 3-month only showed ~2-3% weight loss.
Resolution Criteria
Resolves YES if Wave reports mean total body weight loss of 5% or greater from baseline in the 240mg cohort at 6 months in any public disclosure. Resolves NO if weight loss is below 5% or if data is not reported by June 30, 2026.
Resolution Source
Wave Life Sciences press release, conference presentation, or SEC filing
Source Trigger
WVE-007 6-month data is the single most important near-term catalyst; Phase I 240mg single-dose showed fat loss but limited total body weight loss at 3 months
Full multi-lens equity analysis